Los Angeles Capital Management LLC Has $220,000 Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Los Angeles Capital Management LLC cut its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 28.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 59,805 shares of the company’s stock after selling 23,912 shares during the quarter. Los Angeles Capital Management LLC owned 0.08% of Zentalis Pharmaceuticals worth $220,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the stock. ProShare Advisors LLC grew its stake in shares of Zentalis Pharmaceuticals by 9.0% during the first quarter. ProShare Advisors LLC now owns 15,436 shares of the company’s stock worth $243,000 after buying an additional 1,274 shares during the last quarter. Values First Advisors Inc. grew its position in Zentalis Pharmaceuticals by 5.4% during the 2nd quarter. Values First Advisors Inc. now owns 74,925 shares of the company’s stock worth $306,000 after acquiring an additional 3,859 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Zentalis Pharmaceuticals by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after purchasing an additional 5,333 shares in the last quarter. Carson Advisory Inc. raised its position in Zentalis Pharmaceuticals by 55.8% in the third quarter. Carson Advisory Inc. now owns 24,570 shares of the company’s stock valued at $90,000 after purchasing an additional 8,800 shares during the last quarter. Finally, Anfield Capital Management LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the second quarter valued at about $40,000.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ZNTL shares. Guggenheim dropped their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a report on Friday. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday. Wedbush raised shares of Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price objective on the stock in a research note on Monday, August 12th. Finally, Oppenheimer restated an “outperform” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Zentalis Pharmaceuticals has an average rating of “Hold” and a consensus price target of $10.00.

Zentalis Pharmaceuticals Stock Down 12.1 %

Shares of NASDAQ ZNTL opened at $3.05 on Tuesday. The company has a market capitalization of $217.34 million, a PE ratio of -1.22 and a beta of 1.74. The firm has a fifty day simple moving average of $3.42 and a 200 day simple moving average of $5.33. Zentalis Pharmaceuticals, Inc. has a twelve month low of $2.66 and a twelve month high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36. As a group, equities analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.76 earnings per share for the current fiscal year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.